Mclarney Manor in Brookfield, MO

Mclarney Manor is a medicare and medicaid certified nursing home in Brookfield, Missouri. It is located in Linn county at Po Box 129, 215 East Pratt, Brookfield, Missouri 64628. You can reach out to the office of Mclarney Manor via phone at (660) 258-7402. This skilled nursing facility has 60 federally certified beds with average occupancy rate of 44.33%. Its legal business name is Tiffany Care Centers Inc and has the following ownership type - For Profit - Corporation.

Mclarney Manor (Medicare CCN 265644) is certified by CMS (Centers for Medicare & Medicaid Services) and participates in both medicare and medicaid program. This means if you are part of medicare or medicaid program, you may consider this nursing facility for your medical needs. It was first certified by CMS in 1996 (28 years certified) and the last quality survey was conducted in January, 2020.

Contact Information

Mclarney Manor
Po Box 129, 215 East Pratt, Brookfield, Missouri 64628
(660) 258-7402


Nursing Home Profile

NameMclarney Manor
LocationPo Box 129, 215 East Pratt, Brookfield, Missouri
Certified ByMedicare and Medicaid
No. of Certified Beds60
Occupancy Rate44.33%
Medicare ID (CCN)265644
Legal Business NameTiffany Care Centers Inc
Ownership TypeFor Profit - Corporation

NPI Associated with this Nursing Home:

Nursing Homes may have multiple NPI numbers. We have found possible NPI number/s associated with Mclarney Manor from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1174511927
Organization NameTIFFANY CARE CENTERS
Doing Business AsMCLARNEY MANOR
Address116 E Pratt St, Brookfield, MO 64628
Phone Number660-258-7402

News Archive

Novel anti-inflammatory agents could control hyper-inflammatory responses to fungal infection

The most frequent fungal threat to humans, Candida albicans, is a common cause oral and genital infection. The fungal infections are often worsened by overwhelming inflammatory responses in the body and cause high mortality among risk groups. Umeå University doctoral student Ava Hosseinzadeh has discovered two novel anti-inflammatory agents, an antioxidant and an anti-inflammatory molecule, which could be used to control the hyper-inflammatory responses to the fungal infection.

Australian-led global guidelines for diagnosis and treatment of women with PCOS

Australian led global guidelines for the diagnosis and treatment of the primary cause of infertility in women will be published simultaneously in three international journals, supported by a suite of health professional and patient resources to improve health outcomes for women with PCOS.

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.

Seattle Children's opens enrollment for first clinical trial of Tumor Paint BLZ-100 for children with brain tumors

Seattle Children's today announced the opening of patient enrollment for the first clinical research trial of the drug Tumor Paint BLZ-100, which is designed to improve surgical outcomes in children with brain tumors – the most common solid tumor cancer in kids.

Read more Medical News

› Verified 9 days ago


NPI Number1477576759
Organization NameTIFFANY CARE CENTERS, INC
Doing Business AsMCLARNEY MANOR
Address116 E Pratt St, Brookfield, MO 64628
Phone Number660-258-7402

News Archive

Novel anti-inflammatory agents could control hyper-inflammatory responses to fungal infection

The most frequent fungal threat to humans, Candida albicans, is a common cause oral and genital infection. The fungal infections are often worsened by overwhelming inflammatory responses in the body and cause high mortality among risk groups. Umeå University doctoral student Ava Hosseinzadeh has discovered two novel anti-inflammatory agents, an antioxidant and an anti-inflammatory molecule, which could be used to control the hyper-inflammatory responses to the fungal infection.

Australian-led global guidelines for diagnosis and treatment of women with PCOS

Australian led global guidelines for the diagnosis and treatment of the primary cause of infertility in women will be published simultaneously in three international journals, supported by a suite of health professional and patient resources to improve health outcomes for women with PCOS.

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.

Seattle Children's opens enrollment for first clinical trial of Tumor Paint BLZ-100 for children with brain tumors

Seattle Children's today announced the opening of patient enrollment for the first clinical research trial of the drug Tumor Paint BLZ-100, which is designed to improve surgical outcomes in children with brain tumors – the most common solid tumor cancer in kids.

Read more Medical News

› Verified 9 days ago


NPI Number1962264218
Organization NameANEW HEALTHCARE OPERATIONS - BROOKFIELD, LLC
Address215 E Pratt St, Brookfield, MO 64628
Phone Number660-258-7402

News Archive

Novel anti-inflammatory agents could control hyper-inflammatory responses to fungal infection

The most frequent fungal threat to humans, Candida albicans, is a common cause oral and genital infection. The fungal infections are often worsened by overwhelming inflammatory responses in the body and cause high mortality among risk groups. Umeå University doctoral student Ava Hosseinzadeh has discovered two novel anti-inflammatory agents, an antioxidant and an anti-inflammatory molecule, which could be used to control the hyper-inflammatory responses to the fungal infection.

Australian-led global guidelines for diagnosis and treatment of women with PCOS

Australian led global guidelines for the diagnosis and treatment of the primary cause of infertility in women will be published simultaneously in three international journals, supported by a suite of health professional and patient resources to improve health outcomes for women with PCOS.

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.

Seattle Children's opens enrollment for first clinical trial of Tumor Paint BLZ-100 for children with brain tumors

Seattle Children's today announced the opening of patient enrollment for the first clinical research trial of the drug Tumor Paint BLZ-100, which is designed to improve surgical outcomes in children with brain tumors – the most common solid tumor cancer in kids.

Read more Medical News

› Verified 9 days ago

Quality Ratings:

Nursing homes vary in the quality of care and services they provide to their residents. The below quality ratings for Mclarney Manor are calculated from three sources - health inspection results, staffing data, and quality measure data. This information gives you an indication of the care Mclarney Manor give to their patients.
Ratings from Surveys (Inspections):
Ratings from Quality Measures:
Ratings from Staffing Data:
Overall Rating:

News Archive

Novel anti-inflammatory agents could control hyper-inflammatory responses to fungal infection

The most frequent fungal threat to humans, Candida albicans, is a common cause oral and genital infection. The fungal infections are often worsened by overwhelming inflammatory responses in the body and cause high mortality among risk groups. Umeå University doctoral student Ava Hosseinzadeh has discovered two novel anti-inflammatory agents, an antioxidant and an anti-inflammatory molecule, which could be used to control the hyper-inflammatory responses to the fungal infection.

Australian-led global guidelines for diagnosis and treatment of women with PCOS

Australian led global guidelines for the diagnosis and treatment of the primary cause of infertility in women will be published simultaneously in three international journals, supported by a suite of health professional and patient resources to improve health outcomes for women with PCOS.

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.

Seattle Children's opens enrollment for first clinical trial of Tumor Paint BLZ-100 for children with brain tumors

Seattle Children's today announced the opening of patient enrollment for the first clinical research trial of the drug Tumor Paint BLZ-100, which is designed to improve surgical outcomes in children with brain tumors – the most common solid tumor cancer in kids.

Read more Medical News

› Verified 9 days ago

Complaints, Fines and Penalties:

Number of Facility Reported Incidents0
Number of Substantiated Complaints0
Number of Fines1
Total Amount of Fines in Dollars$650
Number of Payment Denials0
Total Number of Penalties1

Patients' Stay Experience:

The resident survey data of Mclarney Manor is compared against the national average with the color code indicators: Better than National Average Worse than National Average

Experience MeasureProviderNational Avg.
Percentage of long-stay residents whose need for help with daily activities has increased19.3314.46
Percentage of long-stay residents who lose too much weight7.145.51
Percentage of low risk long-stay residents who lose control of their bowels or bladder29.4148.41
Percentage of long-stay residents with a catheter inserted and left in their bladder01.79
Percentage of long-stay residents with a urinary tract infection02.65
Percentage of long-stay residents who have depressive symptoms2.45.05
Percentage of long-stay residents who were physically restrained00.23
Percentage of long-stay residents experiencing one or more falls with major injury6.063.36
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine97.7393.87
Percentage of long-stay residents who received an antipsychotic medication21.3714.2
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine65.7983.88
Percentage of short-stay residents who newly received an antipsychotic medication01.79
Percentage of long-stay residents whose ability to move independently worsened26.7817.09
Percentage of long-stay residents who received an antianxiety or hypnotic medication16.3919.7
Percentage of high risk long-stay residents with pressure ulcers07.32
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine99.3595.98